Replay of: Mitigating Tissue Damage in Radiation Oncology and Inflammation in Pulmonary Disease: Targeting Pathways of Tissue Injury and Inflammatory Response

October 8, 2025

To access the replay and transcript, please complete the form below:

The virtual panel discussion focused on advances in unmet medical needs for oncology-related radiation exposure and pulmonary disease-related inflammation. Leading oncology and pulmonary medicine clinicians, together with researchers, will share perspectives on emerging data, trial design, clinical practice challenges, and insights into potential therapeutic targets. 

Panelists

Rany Condos, MD is Director of the Interstitial Lung Disease Program and the Post-Covid Program at NYU Langone. Dr. Condos specializes in treating patients with a range of complex pulmonary conditions, including interstitial lung diseases, which cause lung tissue scarring and affect the ability to breathe, such as sarcoidosis and collagen vascular-related lung disease, mycobacterial infections, cystic fibrosis/bronchiectasis, and pulmonary alveolar proteinosis. She has been practicing for more than 20 years and has extensive experience and a robust background in pulmonary and critical care. As an investigator on several clinical trials in tuberculosis, cystic fibrosis, and idiopathic pulmonary fibrosis, she focuses on advancing medical knowledge of immune function and lung diseases and improving patient outcomes through innovative research. She has published work on aerosol-directed immunotherapy in tuberculosis and idiopathic pulmonary fibrosis and holds a patent for inhaled interferon-gamma treatment for lung disease. Dr. Condos also teaches at NYU Grossman School of Medicine.

Pranshu Mohindra, MD, MMM is a radiation oncologist at the University Hospitals Cleveland Medical Center in Cleveland, Ohio, where he serves as Professor and Vice Chair of Operations and Quality for the Department of Radiation Oncology and the Director of the University Hospitals Proton Therapy Center. He is also a senior attending physician with the University Hospitals Seidman Cancer Center. He specializes in the use of advanced radiation modalities including intensity-modulated radiotherapy, volumetric modulated arc therapy, stereotactic body radiotherapy and proton beam therapy/pencil beam scanning intensity modulated proton therapy to treat patients with thoracic cancers including lung cancer, thymic tumors and malignant pleural mesothelioma. Dr. Mohindra has published over 110 peer reviewed manuscripts leading to more than 2400 citations (Google Scholar). His research efforts include evaluating treatment outcomes through institutional and population-based databases, development of early phase clinical trials evaluating both radiation sensitizers and radiation toxicity mitigators or evaluation of modern radiation techniques including proton beam therapy for the management of thoracic/lung, gynecological and hemato-lymphoid malignancies.

Colin G. Chinn, MD, MHS, FACP, RADM MC USN (Ret) is Chief Medical Officer, Humanetics Corporation. Admiral Chinn’s perspectives are drawn from clinical, academic, research, operational, and executive medicine leadership roles across four decades of service in the U.S. Navy, including as the 14th Joint Staff Surgeon where he was the senior medical advisor to the Chairman of the Joint Chiefs of Staff. Dr. Chinn served as Clinical Professor of Medicine and Scholar-in-Residence at the Uniformed Services University in Bethesda, Maryland. He served as a member of the Defense Health Board, an independent advisory board for the Secretary of Defense on military health matters. Dr. Chinn is a Fellow of the American College of Physicians, a member of Delta Omega, the National Public Health Honor Society, and achieved board certification in gastroenterology and internal medicine.

Michael D. Kaytor, PhD is Vice President, Research & Development, Humanetics Corporation. Dr. Kaytor built and leads a world-class team of PhD scientists and manufacturing and regulatory experts on a mission to develop BIO 300 (aka BYOGRAYZ™) as a prophylactic Medical Countermeasure for warfighters, and in its dual-use application to protect against normal tissue damage from ionizing radiation during cancer radiotherapy. In addition, due to the anti-inflammatory and anti-fibrotic properties of BIO 300, Dr. Kaytor is leading efforts to develop the drug for pulmonary inflammatory disease indications. Dr. Kaytor has more than twelve years of experience in this role and has been responsible for winning nearly $40MM in federal and state grants and contracts to fund these research programs.

Hannah Olson, PhD is a Research & Development Scientist at Humanetics Corporation. Dr. Olson is responsible for the non-clinical and clinical research programs supporting the development of BIO 300 for oncology and pulmonary indications. Dr. Olson received her doctoral training from Oregon Health and Science University where her studies focused on understanding the cellular and molecular mechanisms that drive development of organ systems. At Humanetics, Dr. Olson uses her academic background to effectively design and execute nonclinical and clinical studies investigating BIO 300’s radioprotective and anti-inflammatory capabilities in support of moving BIO 300 toward FDA approval as a radioprotectant in oncology and a therapeutic for patients diagnosed with inflammatory pulmonary diseases. Dr. Olson has guided to completion the most recent study reports and regulatory filings directed to the Company’s Phase 1 and Phase 2 clinical studies.